Clarivate Analytics software tools: Drug Research Advisor and Key Pathway Advisor

NON-COMPETITIVE
COMBINED SYNOPSIS / SOLICITATION

Title: Clarivate Analytics software tools: Drug Research Advisor and Key Pathway Advisor

(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued.

(ii) The solicitation number is 75N95019Q00151 and the solicitation is issued as a request for quotation (RFQ).

This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures and FAR Part 12-Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition threshold.

THIS IS A NON-COMPETITIVE (NOTICE OF INTENT) COMBINED SYNOPSIS SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME).

The National Institute on Drug Abuse (NIDA), NIDA Office of Acquisitions - NCATS Section, on behalf of the National Center for Advancing Translational Sciences (NCATS), intends to negotiate and award a purchase order without providing for full and open competition (including brand-name) to Clarivate Analytics (US) LLC, 1500 Spring Garden Street, Fourth Floor, Philadelphia, PA, for Clarivate Analytics software tools: Drug Research Advisor and Key Pathway Advisor.

Pursuant to FAR 13.106(b), the contracting officer has determined that only one source is reasonably available for this software due to exclusive licensing agreements.

(iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2019-02 dated May 6, 2019.

(iv) The associated NAICS code is 511210 and the small business size standard is $38.5 million. No set-aside restriction is applicable.

(v) This acquisition consists of:

Line 1: Clarivate Analytics Drug Research Advisor - Target Druggability, annual license, 3 end users

Line 2: Clarivate Analytics Key Pathway Advicor (KPA), annual license, 3 end users

(vi) Delivery shall be to:

The National Center for Advancing Translational Sciences (NCATS)

9800 Medical Center Drive
Rockville, MD 20850

Delivery shall be within 7 days after receipt of order.

(viii) The provision at FAR clause 52.212-1, Instructions to Offerors - Commercial Items, applies to this acquisition. An addendum applies and is included in this solicitation.

(ix) Offers will be evaluated for technical criteria, price, and past performance. Technical criteria consist of matching the line items identified above. Technical and past performance, when combined, are significantly more important than price.

(x) Offerors are to include a completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications-Commercial Items, with offers.

(xi) The FAR clause at 52.212-4, Contract Terms and Conditions - Commercial Items, applies to this acquisition. Addenda apply, and are included in this solicitation.

(xii) FAR clause at 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders-Commercial Items, applies to this acquisition.

(xv) This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this solicitation must include sufficient information to establish the interested parties' bona-fide capabilities of providing the product or service.

The price quote shall include: unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s); product description; and any other information or factors that may be considered in the award decision. Such factors may include: past performance; special features required for effective program performance; trade-in considerations; probable life of the item selected as compared with that of a comparable item; warranty considerations; maintenance availability; and environmental and energy efficiency considerations. Respondents that believe they are an authorized reseller of this licensed product must demonstrate that they are authorized resellers.

A determination by the Government whether to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered to determine whether to proceed on a non-competitive basis as indicated above, or to conduct a competitive procurement.

(xv) The Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.

All responses must be received by 11:00 a.m. Eastern time on Friday, May 17, 2019, and reference solicitation no. 75N95019Q00151. Responses must be submitted by e-mail to Stuart Kern, Contract Specialist, stuart.kern@nih.gov, 301-402-3334.

.